With experience over 35 years in leadership roles at companies across the biotech and pharmaceutical sector, Legault will be a key part of the team as Egle deploys its technology platforms to construct a drug pipeline of novel immunotherapies targeting suppressor regulatory T cells (Tregs).
Over the past five years, Legault has been at the cutting-edge of innovative oncology therapeutics, serving as director of Syndax Pharmaceuticals, and chairman of the board at Artios Pharma, Bicycle Therapeutics, and Sitryx Therapeutics.
This first-hand experience of wide-ranging novel approaches to treat cancer and autoimmune conditions places Legault in a very strong position as he joins the team at Egle Therapeutics.
In his early career, Legault held global roles including president, CEO and CFO at legacy companies of the Sanofi-Aventis group.
Over the past decades, Legault has continued to build a rich profile of experience, holding C-suite executive roles and serving as a board member at over 20 pharmaceutical and biotechnology companies such as Prosidion Ltd., NPS, Armo, Clementia, Poxel, Amolyt Pharma, Urovant Sciences and others.
Established in early 2020 as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research director, Head of the Translational Immunotherapy Team TransImm at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle's core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca